Treatment of children with high grade glioma with nimotuzumab A 5-year institutional experience
Treatment of children with high grade glioma with nimotuzumab A 5-year institutional experience
复制标题
DOI：
10.4161/mabs.22970
复制
发表时间：
2013-03-01
期刊：
影响因子：
5.3
通讯作者：
Crombet Ramos, Tania
中科院分区：
文献类型：
--
作者：
Cabanas, Ricardo;Saurez, Giselle;Crombet Ramos, Tania
脑瘤是儿童癌症相关死亡的主要原因。在儿童脑肿瘤中检测到表皮生长因子受体（EGFR）的过表达，并且受体密度随着肿瘤分级而增加。尼妥珠单抗是一种靶向EGFR的IgG1抗体。23名患有高级别胶质瘤（HGG）的儿童入组了一个扩大准入项目，在该项目中，尼莫单抗单独或与放化疗联合使用。平均剂量为39次。尼妥珠单抗耐受性良好，抗体治疗产生了生存获益：中位生存时间为32.66个月，2年生存率为54.2%。本研究证实了nimotuzumab长期给药的可行性，并初步证明了预后不良的HGG患者的临床获益。
Brain tumors are a major cause of cancer-related mortality in children. Overexpression of epidermal growth factor receptor (EGFR) is detected in pediatric brain tumors and receptor density appears to increase with tumor grading. Nimotuzumab is an IgG1 antibody that targets EGFR. Twenty-three children with high-grade glioma (HGG) were enrolled in an expanded access program in which nimotuzumab was administered alone or with radio-chemotherapy. The mean number of doses was 39. Nimotuzumab was well-tolerated and treatment with the antibody yielded a survival benefit: median survival time was 32.66 mo and the 2-y survival rate was 54.2%. This study demonstrated the feasibility of prolonged administration of nimotuzumab and showed preliminary evidence of clinical benefit in HGG patients with poor prognosis.